Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
Healthline

What Kind of Inhalers and Nebulizer Treatments Work for Bronchitis?

Just when you think you’ve gotten over that respiratory infection, bronchitis hits. The coughing, chest soreness, and fatigue can really get you down. While acute bronchitis will usually go away ...
Devdiscourse

OMRON Healthcare Surpasses 50 Million Nebulizer Sales, Revolutionizing Respiratory Care

OMRON HEALTHCARE Co., Ltd. has announced that its cumulative sales of nebulizers have exceeded 50 million units. This achievement highlights the company's ongoing mission to improve global respiratory ...
Delaware County Daily Times

Managing COPD During the COVID-19 Pandemic

(StatePoint) Managing chronic obstructive pulmonary disease (COPD) is always important, and especially so right now, as individuals living with a chronic lung disease are at a higher risk of severe ...
BGR

Gilead Has A Plan To Make Remdesivir More Effective Against Coronavirus

Experimental coronavirus drug remdesivir is effective in mild to moderate COVID-19 cases, according to recent research. Remdesivir can't prevent complications or reduce mortality, but Gilead thinks ...

OMRON Healthcare Surpasses 50 Million Nebulizers Sold

OMRON HEALTHCARE Co., Ltd., a global leader in the field of clinically proven, innovative medical equipment for home health monitoring and treatment, announced that cumulative sales of its nebulizers ...
Business Wire

Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis ...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an ...
Business Wire

Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar ...

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the UK’s Medicines and Healthcare ...